9 January 2024 - Canada's Drug Agency recently issued draft recommendation to reimburse Vyloy with conditions.

Today, Astellas Pharma Canada is proud to announce that Health Canada has approved Vyloy (zolbetuximab for injection), which is indicated to be used in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction adenocarcinoma whose tumours are claudin 18.2 positive as determined by a validated test.

Read Astellas press release